RT Journal Article
SR Electronic
T1 Vaginal Microbiota Transplantation (VMT) for treatment of vaginal dysbiosis without the use of antibiotics – A Double-Blinded Randomized Controlled Trial in healthy women with vaginal dysbiosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.28.24309465
DO 10.1101/2024.06.28.24309465
A1 Wrønding, Tine
A1 Vomstein, Kilian
A1 DeLong, Kevin
A1 Lundgaard, Agnete Troen
A1 Mollerup, Sarah
A1 Mortensen, Brynjulf
A1 Bosma, Elleke F.
A1 Hellerung, Ann Marie
A1 Engel, Emilie Vester
A1 Wiil, Klara Dortea
A1 Heintz, Julie Elm
A1 Halkjær, Sofie Ingdam
A1 Hugerth, Luisa W
A1 Hartwig, Tanja Schlaikjær
A1 Petersen, Andreas Munk
A1 Thomsen, Anne Bloch
A1 Westergaard, David
A1 Freiesleben, Nina La Cour
A1 Westh, Henrik
A1 van Hylckama Vlieg, Johan E.T.
A1 Ensign, Laura M.
A1 Nielsen, Henriette Svarre
YR 2024
UL http://medrxiv.org/content/early/2024/07/01/2024.06.28.24309465.abstract
AB Here we describe the first double-blinded, randomized, placebo-controlled trial (RCT) on vaginal microbiota transplantation (VMT) without antibiotics in women with both symptomatic and asymptomatic vaginal dysbiosis. Forty-nine women were randomly assigned to VMT or placebo. The trial did not show a significant conversion to our predefined Lactobacillus-dominated microbiome. However, in participants not initially converting, antiseptic pretreatment before a subsequent VMT led to a 50% conversion rate, associated with an anti-inflammatory shift in gene expression. Metagenomic sequencing and strain-level genetic analysis confirmed donor engraftment in five of 10 women who showed microbiome conversion. Extensive exploration of the microbiome, immune response and metadata revealed differences in baseline energy metabolism in participants who later experienced donor engraftment. Treatments for vaginal dysbiosis are urgently needed and given that VMT can lead to donor engraftment and change the vaginal immune profile, future studies should focus on optimizing this treatment for various women’s health diseases.Competing Interest StatementElleke F. Bosma, Brynjulf Mortensen, Kevin DeLong, and Johan E.T. van Hylckama Vlieg are employees of Freya Biosciences, ApS. Johan E.T. van Hylckama Vlieg, Laura M. Ensign, and Anne Bloch Thomsen are cofounders and shareholders of Freya Biosciences, ApS. Laura M. Ensign is a coinventor on patents and patent applications in the area of microbial transplantation. Laura M. Ensigns arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. All other authors declare that they have no competing interestsClinical TrialNCT04855006Funding StatementThe study was partially funded (i.e., analysis costs) by Freya Biosciences Aps, Fruebjergvej, 2100 Copenhagen, DenmarkAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Randomized Controlled Trial study protocol was approved by the Danish ethical comittee of the capital region of Denmark (Journal-nr.: H-20068230) on the 16th of March 2021 and the Danish Data Protection Agency (Pactius): P-2020-1080. The Randomized Controlled Trial was reported on ClinicalTrials.gov Identifier: NCT04855006. Three amendments were added to the study protocol: first, adding rectal swab collection (approved by the Danish ethical Committee of the capital region of Denmark on the 15th of June 2021), second, sub-study using flow cytometry to study immunological cells in peripheral and menstrual blood (approved by the Danish ethical Committee of the capital region of Denmark on the 6th of December 2021) and third, a sub-study of the impact of antiseptic pretreatment to the participants who did not meet the criteria for successful VMT (approved by the Danish ethical Committee of the capital region of Denmark on the 17th of May 2022). All research was conducted according to the Declaration of Helsinki and all participants provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes